USANA Q3 sales $233M (-15% YoY), EPS $0.78; slashes FY2022 guidance

USANA HEALTH SCIENCES INC

2022-Q3 EPS reported $2.93 revenue$770,641,000

Net sales $233M, down 15% YoY ($274M); diluted EPS $0.78 vs $1.36, down 43%.
Active customers fell 18% to 474,000; Asia Pacific region sales down 17% constant currency.
FY2022 outlook cut: net sales $955-975M (prev. $1,015-1,065M); EPS $3.15-3.40 (prev. $3.85-4.45).
Operating cash flow $29M; cash $247M, debt-free; no share repurchases in quarter.
Management cites COVID disruptions in Asia, stronger USD headwind of ~$15M (6% of sales).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.